Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer

BJU International

Volumn 110, Issue 2, 2012, Pages 201-205

  Nguyen, Paul L ^a   Chen, Ming Hui ^b   Hoffman, Karen E ^c   Chen, Ronald C ^d   Hu, Jim C ^a   Bennett, Charles L ^e   Kattan, Michael W ^f   Sartor, Oliver ^g   Stein, Karen ^h   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EISAI INC   (United States)

Author keywords

Comorbidity; Prostate cancer; Regret

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANGINA PECTORIS; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RECURRENT CANCER; STROKE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARDIOVASCULAR DISEASES; EMOTIONS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PATIENT SATISFACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; SOCIOECONOMIC FACTORS;

EID: 84863443424     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10709.x     Document Type: Article

References (17)

1. Hu JC, Kwan L, Saigal CS et al. Regret in men treated for localized prostate cancer. J Urol 2003; 169: 2279-83 (Pubitemid 36576771)
2. Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001; 19: 72-80 (Pubitemid 32063481)
3. Hu JC, Kwan L, Krupski TL et al. Determinants of treatment regret in low-income, uninsured men with prostate cancer. Urology 2008; 72: 1274-9
4. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology™ PROSTATE CANCER (Version 1.2010). 2010
5. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-7 (Pubitemid 38669187)
6. Daskivich T, Sadetsky N, Kaplan SH et al. Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer. Arch Intern Med 2010; 170: 1396-7
7. Ablin RJ, Sartor O, Bennett CL. Invited commentary: prostate cancer: doing less might be more. Comment on 'Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer'. A rch Intern Med 2010; 170: 1397-9
8. D'Amico AV, Chen MH, Renshaw AA et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-95 (Pubitemid 351159365)
9. Droz JP, Balducci L, Bolla M et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106: 462-9
10. Nguyen PL, Chen MH, Renshaw AA et al. Survival following radiation and androgen suppresion therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys 2010; 76: 337-41
11. Sartor O, McLeod DG, Halabi S et al. The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology 2010; 75: 623-9
12. Vavassori V, Fiorino C, Rancati T et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 2007; 67: 1401-10 (Pubitemid 46467147)
13. Tucker SL, Dong L, Bosch WR et al. Late rectal toxicity on RTOG 94-06: analysis using a mixture lyman model. Int J Radiat Oncol Biol Phys 2010; 78: 1253-60
14. Gore JL, Gollapudi K, Bergman J et al. Correlates of bother following treatment for clinically localized prostate cancer. J Urol 2010; 184: 1309-15
15. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7 (Pubitemid 29211767)
16. Schroeck FR, Krupski TL, Sun L et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008; 54: 785-93
17. Davis JW, Kuban DA, Lynch DF et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001; 166: 947-52 (Pubitemid 32750990)